Molecular Diagnostics. Cepheid recently obtained Emergency Use Authorization from the FDA for the first "point of care" test for the novel coronavirus. Point of care tests are tests that quickly provide results. The test targets multiple regions of the viral genome to provide rapid detection of current and potential future variants of SARS-CoV-2.
See map: Google Maps